Serum markers of apoptosis decrease with age and cancer stage

Results

We determined serum levels of sFas in 204 normal subjects. For all subjects, values for fasting glucose, thyroid panel, and calculated BMI were within the normal range.

Figure 1. Serum sFas levels. The levels of sFas in 204 normal subjects was determined by sandwich ELSA. The frequency distribution of the values across the subjects was analyzed (a). The levels of sFas by gender were plotted (b). The sample population was segregated by gender and the levels of serum sFasL as a function of donor age for female (c) and male (d) subjects were plotted.

Table 1. Serum levels of apoptosis biomarkers.

Biomarker levels were compared by gender. The association of serum levels with donor age was analyzed by Spearman correlation. ^a Mann Whitney U-test comparing serum values in females versus males. ^b Correlation coefficient (r) for Spearman nonparametric correlation analysis of serum biomarker levels and donor age. ^c P value for Spearman nonparametric correlation analysis of serum biomarker levels and donor age.

	sFas (pg/ml)		sFasL (pg/ml)		Cytochrome c (μg/ml)
	female	male	female	male	female	male
mean±SD median (range)	3625±1019 3424 (1592-6498)	4475±1459 4303 (1710-8026)	94.6±22.3 97.9 (45.8-139.4)	91.2±20.8 92.4 (40.6-145.6)	0.712±0.206 0.663 (0.24-1.33)	0.703±0.420 0.566 (0.13-2.22)
gender a	p < 0.0001		p = 0.13		p = 0.053
age r b	0.651	0.647	-0.534	-0.337	-0.719	-0.855
p value c	< 0.0001	< 0.0001	< 0.0001	< 0.001	< 0.0001	< 0.0001

The mean value for sFas was 4107 ± 1352 pg/ml. When the frequency distribution of serum values was analyzed by histogram, a slight hook at the high end was evident (Figure 1a). The results were stratified by gender to further study the distribution. For the samples obtained from the 94 female donors, the mean donor age was 53 and ranged from 21 to 87, while for the 110 male donors, the mean age was 52 and ranged from 22 to 88. Serum levels of sFas were significantly higher in males than in females, comparing by a Mann Whitney test (Figure 1b and Table 1). Mean BMI values were 22.6 ± 1.4 and 22.1 ± 1.6 kg/m2 for women and men, respectively. The difference by gender in sFas levels was still significant after controlling for BMI. When sFas levels were plotted versus the age of the subject, the reason for the high-end hook to the distribution of normal values became apparent. Both genders exhibited an age-dependent increase in sFas values with age (Figure 1c and d).

The serum levels of sFasL were determined in the same subjects. The mean value for sFasL was 92.8 ± 21.5 pg/ml. When the distribution of serum values was analyzed by histogram, a slight hook at the low end was evident (Figure 2a). Again, the results were stratified by gender to further study the distribution. Serum levels of sFasL were not significantly different between genders (Figure 2b and Table 1). Plotting sFasL levels versus the age of the subject revealed that both genders exhibited an age-dependent decrease in sFasL values (Figure 2c and d).

While a role for sFas as an anti-apoptotic factor is accepted in the literature, the pro-apoptotic role of sFasL is more equivocal [15-18]. A third marker for apoptosis was developed. Cytochrome c release from the mitochondria is a sentinel signal initiating apoptosis [21] and serum levels of cyt-c have been used as a marker of apoptosis [22,23]. However, cytochrome c is bound to in serum to leucine-rich alpha-2-glycoprotein-1 which can mask antibody epitopes, potentially interfering with immunoassay quantification [20]. We developed a quantitative western blot using purified cytochrome c to generate a standard curve and interpolate unknown concentrations from serum samples that had been denatured and reduced thereby disrupting binding complexes and enabling the quantification of total cytochrome c levels (Figure 3).

The mean value for serum levels of total cytochrome c was 0.71 ± 0.42 μg/ml. The frequency distribution of serum values was analyzed by histogram and a nonparametric distribution was evident (Figure 4a). When the results were stratified by gender, the difference in mean (and median) values by gender were not significant (Figure 4b and Table 1). Plotting total cytochrome c levels versus the age of the subject revealed that both genders exhibited an age-dependent decrease in total cytochrome c, though the slopes appeared to be different (Figure 4c and d).

Because of the nonparametric distribution of these apoptotic markers, the association of serum levels with donor age was analyzed conservatively by Spearman nonparametric correlation (Table 1). Significant correlations of subject age versus serum marker levels were observed. sFas in serum correlated positively with increasing age among females, among males and among the two combined. In contrast, FasL and total cytochrome c correlated negatively with age. Segregating serum samples by gender and by decade of life enabled statistical comparison of gender values by decade using a nonparametric Mann Whitney test. Between the ages of 41 and 80, females had significantly lower levels of the anti-apoptotic marker sFas compared with men (Figure 5a). The serum levels of the potentially pro-apoptotic sFasL, although higher on average in females, were not significantly different then those in men over the seven decades (Figure 5b). The apoptosis marker cytochrome c exhibited levels that were different between men and women from perimenopausal ages onward (Figure 5c).

Figure 2. Serum sFasL levels. The levels of sFasL in 204 normal subjects was determined by sandwich ELSA. The frequency distribution of the values across the subjects was analyzed (a). The levels of sFasL in all subjects as a function of gender were plotted (b). The sample population was segregated by gender and the levels of serum sFasL as a function of donor age for female (c) and male (d) subjects were plotted.

The observed shifts in the balance of pro- and anti-apoptotic factors (sFasL and sFas, respectively) and the apoptosis marker (cytochrome c) with age are consistent with decreased net apoptosis with increasing age. Neoplasm growth and tumor progression rely in part on blocking apoptosis [24-26]. Serum from a group of women with breast cancer (n = 66) and men with prostate cancer (n=38) were analyzed for sFas, sFasL and total cytochrome c and the distribution of the values compared with age and gender-matched normal values (Table 2). sFas levels were significantly elevated in both breast and prostate cancer. In contrast, sFasL and cytochrome c levels were significantly reduced in both breast and prostate cancer.

Figure 3. Total cytochrome c assay. A quantitative western blot assay was developed to measure total cytochrome c in serum. The assay employed denaturing and reducing conditions to disrupt cytochrome c binding to carrier proteins in serum. The assay utilized serial dilutions of purified cytochrome-c resolved by SDS PAGE and western blotting (a) to generate standard curves (b) by digitally imaging and quantifying the chemiluminescent signal and serum from men (c) and women (d) were analyzed in parallel. Standards and serum samples were analyzed in duplicate.

The association of cancer stage groupingswith apoptosis markers was investigated for breast and prostate cancer. The breast cancer serum values were segregated by stage where stage I is small localized tumors with no spreading to axillary lymph nodes; stage II disease has larger tumors and potential spread to the lymph nodes; stage III disease has spread to other lymph nodes or tissues near the breast; while stage IV is metastatic cancer. For prostate cancer, stage II cancer is localized within the prostate but palpable, stage III cancer has broken through the covering of the prostate but is still regional, and stage IV cancer has spread to other tissues. When the distribution of sFas, sFasL and cytochrome c were profiled by stage using Tukey box plots, discrete patterns were observed (Figure 6).

Serum sFas levels increased with increasing stages of breast cancer (Figure 6a). While stage I disease was not significantly different from normal, stages II, III, and IV were significantly elevated relative to the normal. The more advanced stage III disease was significantly elevated compared to normal and earlier stages, and significantly lower compared to stage IV disease. Metastatic disease (stage IV) was significantly elevated compared with all other stages and had a median value ~2-fold higher then normal and stage I breast cancer. Serum sFas levels in prostate cancer exhibited a similar trend of increasing median values with increasing stage. However, only stage IV disease was significantly different from both normal and stage I disease (Figure 6b).

Serum sFasL levels in breast cancer decreased with increasing stage, with more advanced stages (II, III and IV) significantly different from normal and stage I (Figure 6c). With prostate cancer, sFasL levels decreased significantly between normal and stages II, II and IV (Figure 6d). Similarly, serum cytochrome c levels were significantly reduced between normal and stages I through IV of breast cancer (Figure 6e) and between normal and stages II, II and IV of prostate cancer (Figure 6f). Thus, subjects with cancer have higher anti-apoptotic factors (sFas) in circulation and less proapoptotic factors (sFasL, cytochrome c) in circulation. Also, the more advanced the cancer, the larger the change in circulating levels.

Table 2. Serum levels of apoptosis biomarkers in cancer.

^a Age in years ± standard deviation. A subset of the normal female and male groups were age- and gender-matched to the specific cancers. ^b Mann Whitney U-test comparing serum values in breast and prostate cancer subjects to age- and gender matched normal subjects.

	female NL	BCA	male NL	PCA
n	70	66	40	38
Age (years)a	-	62 ± 14	-	66 ± 9
sFas (pg/ml)
mean±SD	3585±918	5202±1732	5023±1309	6249±2324
median	3490	4831	5038	5587
range	1603-5877	2651-11990	3048-8026	3462-11580
U-testb	p < 0.001		p < 0.05
sFasL (pg/ml)
mean±SD	94.4±20.1	75.3±26.2	89.0±19.6	69.7±22.0
median	97.3	75.2	92.2	62.2
range	45.9-139.4	15.6-125.0	40.6-130.3	19.4-127.7
U-testb	p < 0.0001		p < 0.0001
Cytochrome c (μg/ml)
mean±SD	0.673±0.266	0.27±0.14	0.458±0.243	0.23±0.09
median	0.601	0.24	0.406	0.21
range	0.239-1.329	0.07-0.74	0.128-1.039	0.09-0.046
U-testb	p < 0.0001		p < 0.0001

Discussion

Apoptosis, originally believed to be a process with only negative effects, now is recognized to balance the beneficial potential of eliminating damaged cells against the pathological effects of deleterious cell death (e.g. neurodegenerative disease) [27]. Failures in apoptosis can contribute to the senescent cell phenotype as well as rogue cell proliferation [28]. It has been shown that apoptosis is an important cellular defense mechanism in maintaining genetic stability, and centenarians who have aged successfully possess cells that are more prone to apoptosis [29]. The major age related disease leading to mortality is cardiovascular disease. Studies have shown that apoptotic cell death effect cardiac tissue, and in addition, cells that avoid apoptosis participate in the progression of atherosclerosis [30,31]. Cancer, another leading cause of mortality, arises from neoplastic progression through avoidance of apoptosis [32]. In addition, dysregulation of Fas/FasL mediated apoptosis can contribute to the pathogenesis of pulmonary [33,34] liver [35], and neoplastic [36] fibrosis.

Studies with mice having Fas/FasL mutations suggest that that a major function of Fas-mediated apoptosis is the elimination of activated immune cells from the peripheral circulation [37]. Similarly, humans with autoimmune lymphoproliferative syndrome have mutations in Fas [38,39]. Maintenance of Fas apoptosis signaling is a crucial feature for successful immune aging [40]. In young immune fit individuals, stimulation of T cells leads to upregulation of Fas, FasL, and Fas/FasL engagement-induced apoptosis signaling causing cell death which eliminates the majority of T cells that are activated in response to a stimulus, thereby preventing the accumulation of autoreactive T cells. An age-related impairment of Fas/FasL mediated apoptosis is believed to contribute to compromised regulation of the immune system and immunosenscence [28]. The age related shift in favor of reduced apoptosis (higher sFas with lower sFasL and total cytochrome c) may contribute to reduced clearance of immune cells leading to a state of chronic inflammation [27]. A chronic inflammatory state may underlie a number of pathologies including cancer [41], cardiovascular disease [42,43], diabetes mellitus [44], frailty [45,46], osteoporosis [47], rheumatoid arthritis [48], and cognitive disorders such as Alzheimers and Parkinson's disease [49-51]. It is of note that the pro-inflammatory marker interleukin-6 appears to be protective against apoptosis [52-55], its serum levels are known to increase with increasing age [56] and have an inverse correlation with Fas-induced apoptosis [57].

In the immune system, Fas and FasL are involved in down-regulation of immune reactions as well as in T cell-mediated cytotoxicity [58]. In cancer, malignant cells inhibit the expression of membrane-bound Fas and express FasL which triggers tumor-infiltrating lympho-cyte apoptotic cell death [59]. In contrast to their membrane-bound forms, soluble sFas and sFasL exhibit different patterns. The levels of sFas and sFasL have been measured independently in separate studies in different populations of normal subjects [60,61] and subjects with breast cancer [62-64] and prostate cancer [65,66]. Similarly, serum cytochrome c has been measured as a marker of apoptotic cell death [19,67] and in cancer [21,68-70]. In general, serum Fas was elevated in cancer patients while sFasL levels were elevated or reduced, depending on the cancer group. Interpretation of published results on serum cytochrome c are complicated by the recent observation that cytochrome c exists in a complex with leucine-rich alpha-2-glycoprotein-1 in serum which alters immunoreactivity [20]. Thus, it is not clear whether studies measuring cytochrome c directly in serum are quantifying a free (unbound) pool or a pool reflecting some combination of free and complexed cytochrome c. In the current study, levels of 500 ng/ml total cytochrome c were measured on average in the normal population, which is at least 10-fold higher then published values [20,71,70].

Figure 4. Serum total cytochrome c levels. The levels of total cytochrome c in 204 normal subjects were determined as depicted in Figure 3. The frequency distribution of the values across the subjects was analyzed (a). The levels of total cytochrome c in all subjects by gender was plotted (b). The sample population was segregated by gender and the levels of serum cytochrome c as a function of donor age for female (c) and male (d) subjects were plotted.

Figure 5. Age and gender differences in serum sFas,. sFasL and total cytochrome c levels. The serum levels of the apoptotic biomarkers were segregated by gender and by decade. Tukey box and whiskers plots (female clear boxes, male shaded boxes) of sFas (a), sFasL (b) and total cytochrome c (c) depicting the top, bottom, and line through the middle of the box correspond to the 75th percentile (top quartile), 25th percentile (bottom quartile), and 50th percentile (median) respectively. The error bar-like whiskers depict 1.5 x the interquartile range and the solid circles represent outliers. Comparisons between genders were performed conservatively by Mann Whitney U-test.

In a study of 204 clinically defined normal subjects, serum levels of sFas increased while sFasL and total cytochrome c decreased with increasing subject age. In addition, the age-related elevation of sFas was significantly higher, while total cytochrome c was significantly lower in males from their 40's and 50's onward. This is the first report describing the distribution of these multiple markers in a single, well-defined normal population. The healthy normal group had extensive exclusion criteria to minimize confounding due to age-related conditions. Aging is a loss of homeostasis and pathologies traditionally referred to as age-related diseases (e.g. - cardiovascular disease, cancer, diabetes, Alzheimer's, osteoporosis) can be considered as manifestations of fast aging [72]. Given the correlations observed between donor age and the apoptosis markers in the normal healthy group, the expansion of the study group to include age-related diseases (whose serum values would reflect fast aging) might be expected to broaden the differences in these serum markers.

Figure 6. Serum markers of apoptosis and tumor stage. Subjects with breast cancer (a, c, e), or prostate cancer (b, d, f) were stratified by stage and the distribution of sFas (a, b), sFasL (c, d) and cytochrome c (e, f) stratified by staging was determined. The solid horzontal bars depict the median values. For breast cancer, stage I tumor size (T) < 2 cm across and cancer cells have not spread to axillary lymph nodes (N). For stage II, T < 2 cm across and the cancer has spread to the lymph nodes under the arm (N positive) or T is 2 to 5 cm and N is negative. In stage III, T > 5 cm or it has spread to other lymph nodes or tissues near the breast. Stage IV is metastatic cancer. The convention for prostate cancer staging was that in stage I, cancer is found in the prostate only. In stage II, cancer is more advanced than in stage I, but has not spread outside the prostate. In stage III, cancer has spread beyond the outer layer of the prostate to nearby tissues. Stage IV is characterized by distant metastasis. Comparison between group median values was performed by Mann Whitney t-test, where * = p < 0.05, ** = p < 0.005, *** = p < 0.0001. Numbers in parenthesis indicate number of subjects in each group.

The observed shift in the balance to decreased apoptosis may contribute to age-associated increases in diseases characterized by failure of normal apoptosis (e.g. - cancer, arthritis, cardiovascular disease). Indeed, in both breast and prostate cancer, correlative data on serum sFas, sFasL and total cytochrome c that were consistent with a shift toward decreasing apoptosis were also observed in the current study. Finally, many observations indicate that women have a longer life expectancy than men, that mortality and morbidity are higher in men than in women and this gender difference is constant in cardiovascular disease, cancer and dementia [73]. The observed gender differences in apoptosis markers - higher sFas and reduced sFasL and total cytochrome c - which are of indicative of dysregulated apoptosis would be consistent with the increased mortality and morbidity in men.

Acknowledgments

This research was supported by NIH grants CA87311 and CA113865 (N.S.F.), Department of Defense grants W81XWH-04-1-0844 and DAMD17-02-0684 (N.S.F.), and the Johns Hopkins Bayview Medical Center General Clinical Research Center, NIH/NCRR grant M01RR02719. N.K. was supported by NIH grant T35 AG-26758, the American Federation on Aging Research and the John A. Hartford Foundation.

Conflicts of Interest

There is no conflict of interest for any of the authors.

References

• 1. Muradian K and Schachtschabel DO. The role of apoptosis in aging and age-related disease: update. Z Gerontol Geriatr. 2001; 34: 441 -446. [PubMed] .
• 2. Pollack M , Phaneuf S , Dirks A and Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci. 2002; 959: 93 -107. [PubMed] .
• 3. Adams JD , Mukherjee SK , Klaidman LK , Chang ML and Yasharel R. Apoptosis and oxidative stress in the aging brain. Ann N Y Acad Sci. 1996; 786: 135 -151. [PubMed] .
• 4. Sastre J , Pallardo FV and Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life. 2000; 49: 427 -435. [PubMed] .
• 5. Kujoth GC , Hiona A , Pugh TD , Someya S , Panzer K , Wohlgemuth SE , Hofer T , Seo AY , Sullivan R , Jobling WA , Morrow JD and Van Remmen H. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science. 2005; 309: 481 -484. [PubMed] .
• 6. Arck PC , Overall R , Spatz K , Liezman C , Handjiski B , Klapp BF , Birch-Machin MA and Peters EM. Towards a "free radical theory of graying": melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. Faseb J. 2006; 20: 1567 -1569. [PubMed] .
• 7. Fraker PJ and Lill-Elghanian DA. The many roles of apoptosis in immunity as modified by aging and nutritional status. J Nutr Health Aging. 2004; 8: 56 -63. [PubMed] .
• 8. Kim R , Emi M , Tanabe K , Uchida Y and Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004; 100: 2281 -2291. [PubMed] .
• 9. Gupta S Molecular mechanisms of apoptosis in the cells of the immune system in human aging. Immunol Rev. 2005; 205: 114 -129. [PubMed] .
• 10. Schneider P and Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv. 2000; 74: 281 -286. [PubMed] .
• 11. Sharma K , Wang RX , Zhang LY , Yin DL , Luo XY , Solomon JC , Jiang RF , Markos K , Davidson W , Scott DW and Shi YF. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther. 2000; 88: 333 -347. [PubMed] .
• 12. Cheng J , Zhou T , Liu C , Shapiro JP , Brauer MJ , Kiefer MC , Barr PJ and Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263: 1759 -1762. [PubMed] .
• 13. Papoff G , Cascino I , Eramo A , Starace G , Lynch DH and Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol. 1996; 156: 4622 -4630. [PubMed] .
• 14. Tanaka M , Suda T , Takahashi T and Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. Embo J. 1995; 14: 1129 -1135. [PubMed] .
• 15. Kim JM , Kim JS , Jung HC , Song IS and Kim CY. Apoptosis of human gastric epithelial cells via caspase-3 activation in response to Helicobacter pylori infection: possible involvement of neutrophils through tumor necrosis factor alpha and soluble Fas ligands. Scand J Gastroenterol. 2000; 35: 40 -48. [PubMed] .
• 16. Serrao KL , Fortenberry JD , Owens ML , Harris FL and Brown LA. Neutrophils induce apoptosis of lung epithelial cells via release of soluble Fas ligand. Am J Physiol Lung Cell Mol Physiol. 2001; 280: L298 -L305. [PubMed] .
• 17. Suda T , Hashimoto H , Tanaka M , Ochi T and Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997; 186: 2045 -2050. [PubMed] .
• 18. Mogi M , Fukuo K , Yang J , Suhara T and Ogihara T. Hypoxia stimulates release of the soluble form of fas ligand that inhibits endothelial cell apoptosis. Lab Invest. 2001; 81: 177 -184. [PubMed] .
• 19. Abu-Qare AW and Abou-Donia MB. Biomarkers of apoptosis: release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2'-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J Toxicol Environ Health B Crit Rev. 2001; 4: 313 -332. [PubMed] .
• 20. Cummings C , Walder J , Treeful A and Jemmerson R. Serum leucine-rich alpha-2-glycoprotein-1 binds cytochrome c and inhibits antibody detection of this apoptotic marker in enzyme-linked immunosorbent assay. Apoptosis. 2006; 11: 1121 -1129. [PubMed] .
• 21. Renz A , Burek C , Mier W , Mozoluk M , Schulze-Osthoff K and Los M. Cytochrome c is rapidly extruded from apoptotic cells and detectable in serum of anticancer-drug treated tumor patients. Adv Exp Med Biol. 2001; 495: 331 -334. [PubMed] .
• 22. Ben-Ari Z , Schmilovotz-Weiss H , Belinki A , Pappo O , Sulkes J , Neuman MG , Kaganovsky E , Kfir B , Tur-Kaspa R and Klein T. Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J Intern Med. 2003; 254: 168 -175. [PubMed] .
• 23. Adachi N , Hirota M , Hamaguchi M , Okamoto K , Watanabe K and Endo F. Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome. Clin Chim Acta. 2004; 342: 127 -136. [PubMed] .
• 24. Pan H , Yin C and Van Dyke T. Apoptosis and cancer mechanisms. Cancer Surv. 1997; 29: 305 -327. [PubMed] .
• 25. Staunton MJ and Gaffney EF. Apoptosis: basic concepts and potential significance in human cancer. Arch Pathol Lab Med. 1998; 122: 310 -319. [PubMed] .
• 26. Reed JC Dysregulation of apoptosis in cancer. J Clin Oncol. 1999; 17: 2941 -2953. [PubMed] .
• 27. Warner HR Aging and regulation of apoptosis. Curr Top Cell Regul. 1997; 35: 107 -121. [PubMed] .
• 28. Hsu HC , Scott DK and Mountz JD. Impaired apoptosis and immune senescence - cause or effect. Immunol Rev. 2005; 205: 130 -146. [PubMed] .
• 29. Franceschi C , Monti D , Scarfi MR , Zeni O , Temperani P , Emilia G , Sansoni P , Lioi MB , Troiano L and Agnesini C. Genomic instability and aging. Studies in centenarians (successful aging) and in patients with Down's syndrome (accelerated aging). Ann N Y Acad Sci. 1992; 663: 4 -16. [PubMed] .
• 30. Bromme HJ and Holtz J. Apoptosis in the heart: when and why. Mol Cell Biochem. 1996; 163-164: 261 -275. [PubMed] .
• 31. Olivetti G , Abbi R , Quaini F , Kajstura J , Cheng W , Nitahara JA , Quaini E , Di Loreto C , Beltrami CA , Krajewski S , Reed JC and Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997; 336: 1131 -1141. [PubMed] .
• 32. O'Brien DI , Nally K , Kelly RG , O'Connor TM , Shanahan F and O'Connell J. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets. 2005; 9: 1031 -1044. [PubMed] .
• 33. Santiago B , Galindo M , Rivero M and Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 2001; 44: 1667 -1676. [PubMed] .
• 34. Tanaka T , Yoshimi M , Maeyama T , Hagimoto N , Kuwano K and Hara N. Resistance to Fas-mediated apoptosis in human lung fibroblast. Eur Respir J. 2002; 20: 359 -368. [PubMed] .
• 35. Canbay A , Higuchi H , Bronk SF , Taniai M , Sebo TJ and Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 2002; 123: 1323 -1330. [PubMed] .
• 36. Peng Z , Zhang Y , Gu W , Wang Z , Li D , Zhang F , Qiu G and Xie K. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int J Oncol. 2005; 26: 467 -473. [PubMed] .
• 37. Crispe IN Fatal interactions: Fas-induced apoptosis of mature T cells. Immunity. 1994; 1: 347 -349. [PubMed] .
• 38. Fisher GH , Rosenberg FJ , Straus SE , Dale JK , Middleton LA , Lin AY , Strober W , Lenardo MJ and Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995; 81: 935 -946. [PubMed] .
• 39. Rieux-Laucat F , Le Deist F , Hivroz C , Roberts IA , Debatin KM , Fischer A and de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995; 268: 1347 -1349. [PubMed] .
• 40. Herndon FJ , Hsu HC and Mountz JD. Increased apoptosis of CD45RO- T cells with aging. Mech Ageing Dev. 1997; 94: 123 -134. [PubMed] .
• 41. Aggarwal BB , Shishodia S , Sandur SK , Pandey MK and Sethi G. Inflammation and cancer: how hot is the link. Biochem Pharmacol. 2006; 72: 1605 -1621. [PubMed] .
• 42. Osiecki H The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev. 2004; 9: 32 -53. [PubMed] .
• 43. Diomedi M , Leone G and Renna A. The role of chronic infection and inflammation in the pathogenesis of cardiovascular and cerebrovascular disease. Drugs Today (Barc). 2005; 41: 745 -753. [PubMed] .
• 44. Duncan BB and Schmidt MI. The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther. 2006; 8: 7 -17. [PubMed] .
• 45. Leng S , Chaves P , Koenig K and Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002; 50(7): 1268 -1271. [PubMed] .
• 46. Walston J , McBurnie MA , Newman A , Tracy RP , Kop WJ , Hirsch CH , Gottdiener J and Fried LP. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002; 162: 2333 -2341. [PubMed] .
• 47. Ginaldi L , Di Benedetto MC and De Martinis M. Osteoporosis, inflammation and ageing. Immun Ageing. 2005; 2: 14 [PubMed] .
• 48. Wong SH and Lord JM. Factors underlying chronic inflammation in rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 2004; 52: 379 -388. [PubMed] .
• 49. McGeer PL and McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004; 1035: 104 -116. [PubMed] .
• 50. Perry CG , Cleland SJ , Connell JM , Petrie JR and Sattar N. Low grade inflammation is notably suppressed by conventional anti-inflammatory treatment: a randomised crossover trial. Heart. 2004; 90: 804 -805. [PubMed] .
• 51. Wersinger C and Sidhu A. An inflammatory pathomechanism for Parkinson's disease. Curr Med Chem. 2006; 13: 591 -602. [PubMed] .
• 52. Biffl WL , Moore EE , Moore FA , Barnett CC Jr , Carl VS and Peterson VN. Interleukin-6 delays neutrophil apoptosis. Arch Surg. 1996; 131: 24 -29. [PubMed] .
• 53. Bansal MB , Kovalovich K , Gupta R , Li W , Agarwal A , Radbill B , Alvarez CE , Safadi R , Fiel MI , Friedman SL and Taub RA. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol. 2005; 42: 548 -556. [PubMed] .
• 54. Chao KC , Chao KF , Chuang CC and Liu SH. Blockade of interleukin 6 accelerates acinar cell apoptosis and attenuates experimental acute pancreatitis in vivo. Br J Surg. 2006; 93: 332 -338. [PubMed] .
• 55. Malara N , Foca D , Casadonte F , Sesto MF , Macrina L , Santoro L , Scaramuzzino M , Terracciano R and Savino R. Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle. 2008; 7: 3235 -3245. [PubMed] .
• 56. Giuliani N , Sansoni P , Girasole G , Vescovini R , Passeri G , Passeri M and Pedrazzoni M. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol. 2001; 36: 547 -557. [PubMed] .
• 57. Kovalovich K , Li W , DeAngelis R , Greenbaum LE , Ciliberto G and Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem. 2001; 276: 26605 -26613. [PubMed] .
• 58. Siegel RM , Chan FK , Chun HJ and Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000; 1: 469 -474. [PubMed] .
• 59. Abrahams VM , Kamsteeg M and Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol. 2003; 25: 19 -30. [PubMed] .
• 60. Seishima M , Takemura M , Saito K , Sano H , Minatoguchi S , Fujiwara H , Hachiya T and Noma A. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Clin Chem. 1996; 42: 1911 -1914. [PubMed] .
• 61. Ichikura T , Majima T , Uchida T , Okura E , Ogawa T and Mochizuki H. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep. 2001; 8: 311 -314. [PubMed] .
• 62. Ueno T , Toi M and Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999; 5: 3529 -3533. [PubMed] .
• 63. Mullauer L , Mosberger I , Grusch M , Rudas M and Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol. 2000; 190: 20 -30. [PubMed] .
• 64. Sheen-Chen SM , Chen HS , Eng HL and Chen WJ. Circulating soluble Fas in patients with breast cancer. World J Surg. 2003; 27: 10 -13. [PubMed] .
• 65. Furuya Y , Fuse H and Masai M. Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res. 2001; 21: 3595 -3598. [PubMed] .
• 66. Furuya Y , Nagakawa O and Fuse H. Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer. Endocr J. 2003; 50: 629 -633. [PubMed] .
• 67. Jemmerson R , LaPlante B and Treeful A. Release of intact, monomeric cytochrome c from apoptotic and necrotic cells. Cell Death Differ. 2002; 9: 538 -548. [PubMed] .
• 68. Herrmann PC , Gillespie JW , Charboneau L , Bichsel VE , Paweletz CP , Calvert VS , Kohn EC , Emmert-Buck MR , Liotta LA and Petricoin EF 3rd. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003; 3: 1801 -1810. [PubMed] .
• 69. Barczyk K , Kreuter M , Pryjma J , Booy EP , Maddika S , Ghavami S , Berdel WE , Roth J and Los M. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer. 2005; 116: 167 -173. [PubMed] .
• 70. Osaka A , Hasegawa H , Tsuruda K , Inokuchi N , Yanagihara K , Yamada Y , Aoyama M , Sawada T and Kamihira S. Serum cytochrome c to indicate the extent of ongoing tumor cell death. Int J Lab Hematol. 2009; 31: 307 -14. [PubMed] .
• 71. Hosoya M , Kawasaki Y , Katayose M , Sakuma H , Watanabe M , Igarashi E , Aoyama M , Nunoi H and Suzuki H. Prognostic predictive values of serum cytochrome c, cytokines, and other laboratory measurements in acute encephalopathy with multiple organ failure. Arch Dis Child. 2006; 91: 469 -472. [PubMed] .
• 72. Blagosklonny MV Validation of anti-aging drugs by treating age-related diseases. Aging. 2009; 1: 281 -288. .
• 73. Miniño AM , Heron M , Smith BL and Kochanek KD. Deaths: Final data for 2004. Natl Vital Stat Rep. 2007; 55: 1 -119. .